Home
|
About us
|
Contact us
About AWMSG
All Wales Medicines Strategy Group (AWMSG)
New Medicines Group (NMG)
All Wales Prescribing Advisory Group (AWPAG)
Meetings
Appraisals
Appraisal information
Patients/carers/patient organisations
Healthcare professionals
Pharmaceutical industry
Search and reports
Search and browse
Reports
Medicines management
About
Forthcoming work programme
National prescribing indicators
Clinical effectiveness prescribing programme
Appraisal monitoring
In-patient medication administration record
Patient information leaflets
Library
darunavir/cobicistat (Rezolsta®)
Reference No. 2193
Publication date:
02/09/2015
Appraisal information
darunavir/cobicistat (Rezolsta®) 800 mg/150 mg film-coated tablet
Company:
Janssen-Cilag Ltd
BNF category:
Infections
NMG meeting date:
10/06/2015
AWMSG meeting date:
15/07/2015
Submission Type:
Full Submission
Status:
Recommended
Advice No:
2115
Ratification by Welsh Government:
27/08/2015
Current Progress
Submission
received
NMG
meeting
AWMSG
meeting
Ratification by
Welsh Government
AWMSG advice
Darunavir/cobicistat (Rezolsta®) is recommended as an option for use within NHS Wales in combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older.
Final Appraisal Recommendation (FAR)
Download
darunavir-cobicistat (Rezolsta) 2193 FAR
AWMSG Secretariat Appraisal Report (ASAR)
Download
darunavir-cobicistat (Rezolsta) 2193 ASAR
Clinical Expert (CE) Summary
Download
darunavir-cobicistat (Rezolsta) 2193 CE summary